Nevertheless, considering that aspirin has been retrospectively shown to reduce the risk of various types of cancer (48), the efficacy of aspirin in combination with the MEK inhibitor may be evaluated by additional approaches including a real-world data analysis of patients prescribed with trametinib with or without regular use of aspirin. This evidence concerns the gene MAP2K7 and cancer.